Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 29141-29150 Newer>

The Motley Fool March 17, 2008 Brian Orelli	Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis...
The Motley Fool March 17, 2008 Alyce Lomax	Something in the Air for Aeropostale This retailer may be a fashionable stock idea for long-term investors.
The Motley Fool March 17, 2008 Rick Aristotle Munarriz	This Reverse Split Will Burn You Online retailer Bluefly is another penny stock throwing its hat into the reverse split ring in order to maintain its Nasdaq listing.
The Motley Fool March 17, 2008 Todd Wenning	Yes, There Is Political Risk In just the past three months, 2008 has served as a stark reminder that, yes, there is political risk to consider when you invest overseas. Now's the time to check your risk-reward profile.
The Motley Fool March 17, 2008 Rick Aristotle Munarriz	You're Wrong About This Call, Mr. Market Downgrades of TD AMERITRADE and Charles Schwab may lead to good sales on these discount brokers.
The Motley Fool March 17, 2008 James Early	The Worst Stocks to Own Does your portfolio contain stocks with these bad qualities? If so, get out now before it's too late.
The Motley Fool March 17, 2008 Brian Richards	Roundtable: What Bear Stearns' Fallout Means for Investors A discussion about the fallout of the collapse of Bear Stearns.
The Motley Fool March 17, 2008 Rich Duprey	Foolish Forecast: Healthways Looking Ill In advance of earnings, analysts wonder if managed-care provider Healthways will meet its own scaled back expectations.
The Motley Fool March 17, 2008 Tom Hutchinson	Credit Crunch Cuts Down Bear Stearns Bear Stearns sells itself to avoid filing for bankruptcy.
The Motley Fool March 17, 2008 Brian Lawler	Parsing the Details With Dendreon Development-stage drugmaker Dendreon announces that it is changing its pivotal phase 3 clinical trial for its lead drug.
<Older 29141-29150 Newer> Return to current articles.